Ultragenyx Pharmaceutical (RARE) Receivables - Other (2017 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed Receivables - Other for 9 consecutive years, with $1.0 million as the latest value for Q4 2025.
- Quarterly Receivables - Other fell 50.0% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 50.0% year-over-year, with the annual reading at $1.0 million for FY2025, 50.0% down from the prior year.
- Receivables - Other for Q4 2025 was $1.0 million at Ultragenyx Pharmaceutical, down from $2.1 million in the prior quarter.
- The five-year high for Receivables - Other was $16.0 million in Q4 2021, with the low at $200000.0 in Q1 2024.
- Average Receivables - Other over 5 years is $3.9 million, with a median of $2.4 million recorded in 2023.
- The sharpest move saw Receivables - Other crashed 98.43% in 2024, then soared 1100.0% in 2025.
- Over 5 years, Receivables - Other stood at $16.0 million in 2021, then crashed by 60.0% to $6.4 million in 2022, then tumbled by 82.81% to $1.1 million in 2023, then surged by 81.82% to $2.0 million in 2024, then tumbled by 50.0% to $1.0 million in 2025.
- According to Business Quant data, Receivables - Other over the past three periods came in at $1.0 million, $2.1 million, and $900000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.